002317.SZ
众生药业
SZSE · Healthcare · C 制造业 · CN
CNY 25.34
−3.17%Year over year
Reported trailing growth
- Revenue
- +2.1%
- EBITDA
- —
- EBIT
- +229.7%
- EPS
- +207.7%
- Free cash flow
- +8.9%
- Operating cash flow
- +22.3%
Forward estimates
Based on analyst estimates
- Revenue
- +1.5%
- EBITDA
- +44.9%
- EPS
- +39.7%
Three-year CAGR
- Revenue
- -1.9%
- EBITDA
- -3.8%
- EBIT
- -7.3%
- Net income
- -5.0%
- EPS
- -6.2%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026